MCID: SKN019
MIFTS: 67

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 56 15
Cutaneous Melanoma 12 30 6 15 17 74
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 45
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD9CM 36 172 172.9
MeSH 45 C562393
NCIt 51 C3510
SNOMED-CT 69 93655004
ICD10 34 C43 C43.9

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and acral lentiginous melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is LINC00937 (Long Intergenic Non-Protein Coding RNA 937), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Triamcinolone and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.7 BRAF CDKN2A CDKN2B MITF NRAS TP53
2 acral lentiginous melanoma 32.3 BRAF CDKN2A NRAS
3 melanoma 30.7 BRAF CDKN2A MCAM MIA MITF NRAS
4 mucosal melanoma 30.5 BRAF MITF NRAS
5 vitiligo-associated multiple autoimmune disease susceptibility 1 30.2 MITF PMEL TYR
6 meningeal melanomatosis 30.1 CDKN2A NRAS TP53
7 spitz nevus 30.1 BRAF CDKN2A TP53
8 li-fraumeni syndrome 30.0 CDKN1A CDKN2A MDM2 TP53
9 melanoma, uveal 30.0 BRAF CDKN2A MITF MMP2 NRAS PMEL
10 retinoblastoma 29.9 CDKN1A CDKN2A MDM2 TP53
11 thyroid cancer 29.6 BRAF CASP3 CDKN1A NRAS TP53
12 lymphoma, non-hodgkin, familial 29.5 BRAF CASP3 CDKN2B MDM2 NRAS TP53
13 squamous cell carcinoma 29.4 BRAF CDKN2A MMP2 NME1 PTGS2 TP53
14 hepatocellular carcinoma 27.2 CASP3 CDKN1A CDKN2A DRAIC FGF2 MMP2
15 breast cancer 27.1 BRAF CASP3 CDKN1A DRAIC FGF2 MDM2
16 melanoma, cutaneous malignant 2 12.6
17 melanoma, cutaneous malignant 3 12.6
18 melanoma, cutaneous malignant 5 12.6
19 melanoma, cutaneous malignant 6 12.6
20 melanoma, cutaneous malignant 9 12.6
21 melanoma, cutaneous malignant 10 12.6
22 melanoma, cutaneous malignant 8 12.6
23 melanoma, cutaneous malignant 4 12.4
24 melanoma, cutaneous malignant 7 12.4
25 superficial spreading melanoma 11.5
26 skin carcinoma 11.5
27 skin/hair/eye pigmentation, variation in, 3 11.4
28 tumor predisposition syndrome 11.3
29 skin amelanotic melanoma 11.1
30 amelanotic melanoma 11.1
31 spitzoid melanoma 11.0
32 melanoma in congenital melanocytic nevus 11.0
33 meningeal melanoma 10.5 CDKN2A MITF
34 malignant leptomeningeal tumor 10.5 CDKN2A MITF
35 albinism, ocular, with late-onset sensorineural deafness 10.4 MITF TYR
36 nevus of ota 10.4 BRAF TP53
37 gallbladder melanoma 10.4 MITF PMEL
38 albinism, ocular, with sensorineural deafness 10.4 MITF TYR
39 ring chromosome 7 10.4 MDM2 TP53
40 zika virus infection 10.4 MDM2 TP53
41 halo nevi 10.4 PMEL TYR
42 scrotal carcinoma 10.4 CDKN2A CDKN2B TP53
43 histiocytic sarcoma 10.4 BRAF CDKN2A
44 bladder squamous cell carcinoma 10.4 BRAF CDKN2A TP53
45 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4 MITF PMEL TYR
46 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
47 pigmented basal cell carcinoma 10.3 MITF TYR
48 hermansky-pudlak syndrome 3 10.3 MITF PMEL TYR
49 vulvar intraepithelial neoplasia 10.3 MMP2 TP53
50 leukemia, acute lymphoblastic 3 10.3 CDKN2A CDKN2B TP53

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Melanoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2 behavior/neurological MP:0005386 10.41 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
3 hematopoietic system MP:0005397 10.41 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
4 cardiovascular system MP:0005385 10.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
5 cellular MP:0005384 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
6 endocrine/exocrine gland MP:0005379 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
7 integument MP:0010771 10.38 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
8 growth/size/body region MP:0005378 10.36 BRAF CASP3 CDKN1A CDKN2A MDM2 MITF
9 immune system MP:0005387 10.36 BRAF CASP3 CDKN1A CDKN2A CDKN2B MCAM
10 mortality/aging MP:0010768 10.34 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
11 craniofacial MP:0005382 10.26 BRAF CASP3 CDKN1A MDM2 MITF MMP2
12 embryo MP:0005380 10.25 BRAF CDKN1A CDKN2A MDM2 MITF NRAS
13 neoplasm MP:0002006 10.23 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
14 digestive/alimentary MP:0005381 10.21 BRAF CASP3 CDKN1A CDKN2A MDM2 NRAS
15 nervous system MP:0003631 10.21 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
16 no phenotypic analysis MP:0003012 10.18 CASP3 CDKN1A CDKN2A CDKN2B MCAM MDM2
17 muscle MP:0005369 10.13 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
18 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A FGF2 MITF TP53
19 liver/biliary system MP:0005370 10.11 BRAF CDKN1A CDKN2A MDM2 NME1 NRAS
20 limbs/digits/tail MP:0005371 10.07 BRAF CDKN1A MDM2 MITF NRAS TP53
21 pigmentation MP:0001186 10.02 BRAF CASP3 CDKN2A MDM2 MITF NRAS
22 reproductive system MP:0005389 10 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
23 renal/urinary system MP:0005367 9.92 BRAF CASP3 CDKN1A CDKN2B MDM2 PTGS2
24 skeleton MP:0005390 9.77 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
25 respiratory system MP:0005388 9.7 BRAF CASP3 CDKN1A CDKN2A MMP2 PTGS2
26 vision/eye MP:0005391 9.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MITF

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 732)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Pembrolizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1374853-91-4
7
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
8
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Everolimus Approved Phase 4,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
13
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
14
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
15
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
16
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
17
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
18
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 571190-30-2 5005498 11431660 5330286
19
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
20
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 60-00-4, 62-33-9 6049
25
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 67-43-6
26
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Adalimumab Approved Phase 4 331731-18-1 16219006
29
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
30
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
31
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
32
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
33
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
34
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
35
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
36
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
37
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
38
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
39
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
40
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-88-6, 585-86-4 493591
41
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
42 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
49 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
50 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2630)
# Name Status NCT ID Phase Drugs
1 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
12 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
13 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
14 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
15 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
16 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
17 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
18 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
19 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
20 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
21 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
22 ASCEND: A Study of Cardiovascular Events iN Diabetes Active, not recruiting NCT00135226 Phase 4 Aspirin;Omega-3 Ethyl Esters;Placebo Aspirin;Placebo Omega-3 Ethyl Esters
23 Flu Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
24 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
25 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
26 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
27 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
28 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
29 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
30 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
31 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
32 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
33 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
34 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
35 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
36 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
37 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
38 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
39 Neoadjuvant L19IL2/L19TNF- Pivotal Study Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
40 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
41 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
42 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
43 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
44 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
45 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
46 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed NCT01597908 Phase 3 Dabrafenib;Vemurafenib;Trametinib
47 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
48 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
49 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
50 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 30

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

42
Skin, Lymph Node, Brain, T Cells, Liver, Testes, Kidney

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 2766)
# Title Authors Year
1
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. ( 30769330 )
2019
2
Li-Fraumeni syndrome presenting as cutaneous melanoma in a child: case report and review of literature. ( 30653764 )
2019
3
The accuracy of elastographic strain ratio and ultrasound thickness in the differentiation of thin and thick cutaneous melanoma. ( 31091968 )
2019
4
The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. ( 31095042 )
2019
5
Cutaneous Melanoma in the Elderly: Review of a Growing Problem. ( 31101317 )
2019
6
Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. ( 31042264 )
2019
7
Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. ( 31058533 )
2019
8
Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients. ( 31058535 )
2019
9
Sentinel Lymph Node Biopsy in Patients With Thick Primary Cutaneous Melanoma. ( 31068991 )
2019
10
Tropomyosin-Related Kinase Receptor and Neurotrophin Expression in Cutaneous Melanoma Is Associated with a Poor Prognosis and Decreased Survival. ( 31071716 )
2019
11
NAV2 facilitates invasion of cutaneous melanoma cells by targeting SNAI2 through the GSK-3β/β-catenin pathway. ( 30997569 )
2019
12
Nonvisualization of Sentinel Lymph Nodes by Lymphoscintigraphy in Primary Cutaneous Melanoma: Incidence, Risk Factors, and a Review of Management Options. ( 31008914 )
2019
13
Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome. ( 31012520 )
2019
14
Cutaneous melanoma in patients from western Mexico: Clinical pathology characteristics and their relationship to prognosis. ( 31016713 )
2019
15
Clinicopathologic Features and Prognostic Factors of Primary Cutaneous Melanoma: a Multicenter Study in Korea. ( 31020815 )
2019
16
FARP1 Facilitates Cell Proliferation Through Modulating MAPK Signaling Pathway in Cutaneous Melanoma. ( 31021836 )
2019
17
Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases. ( 31022059 )
2019
18
Cutaneous tumoural melanosis: a presentation of complete regression of cutaneous melanoma. ( 31023480 )
2019
19
Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker. ( 30944615 )
2019
20
Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. ( 30950242 )
2019
21
Reply to: Differences in cutaneous melanoma outcomes with changes in lymphoscintigraphy timings? ( 30954351 )
2019
22
Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous melanoma. ( 30957641 )
2019
23
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. ( 30959471 )
2019
24
Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma. ( 30965022 )
2019
25
Ultraviolet radiation and cutaneous melanoma: a historical perspective. ( 30969182 )
2019
26
Metastatic Cutaneous Melanoma Presenting with Choroidal Metastasis Simulating Primary Uveal Melanoma. ( 30976593 )
2019
27
Health Behaviour Changes of Cutaneous Melanoma Survivors in Slovenia - A Qualitative Study. ( 30984297 )
2019
28
Angiotropism in primary cutaneous melanoma is associated with disease progression and distant metastases: a retrospective study of 179 cases. ( 30903664 )
2019
29
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. ( 30860590 )
2019
30
Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. ( 30863311 )
2019
31
Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma. ( 30871230 )
2019
32
LAG-3 and TIGIT protein expressions in cutaneous melanoma and their relationship with PD-1 tumor-infiltrating lymphocytes. ( 30880064 )
2019
33
Influence of functional variants Asp312Asn and Lys751Gln of Xeroderma Pigmentosum Group D (XPD) and Glutathione S-transferase Mu 1 (GSTM1) and Theta 1 (GSTT1) genes on cutaneous melanoma susceptibility and prognosis. ( 30883948 )
2019
34
Differences in cutaneous melanoma outcomes with changes in lymphoscintigraphy timings? ( 30890284 )
2019
35
Metastatic Cutaneous Melanoma Presenting With Melanoma-Associated Retinopathy. ( 30893173 )
2019
36
Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy". ( 30899087 )
2019
37
Reply to Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy". ( 30899089 )
2019
38
Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. ( 30816996 )
2019
39
Novel lymph node segmentation and proliferation index measurement for skin melanoma biopsy images. ( 30822606 )
2019
40
Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. ( 30833299 )
2019
41
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. ( 30835257 )
2019
42
Utility of Multistep Protocols in the Analysis of Sentinel Lymph Nodes in Cutaneous Melanoma: An Assessment of 194 Cases. ( 30855172 )
2019
43
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. ( 30773503 )
2019
44
Accuracy of partial biopsies in the management of cutaneous melanoma. ( 30773625 )
2019
45
Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines. ( 30774558 )
2019
46
Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case-control study. ( 30787091 )
2019
47
Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. ( 30800067 )
2019
48
Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. ( 30719636 )
2019
49
Declining Recommended Surgery in Primary Cutaneous Melanoma: An Analysis of Risk Factors and Survival. ( 30719760 )
2019
50
Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. ( 30721246 )
2019

Variations for Skin Melanoma

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1910)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5611215 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 0
2 COSM5611210 YAP1 skin,neck,malignant melanoma,NS c.1129C>T p.Q377* 11:102229716-102229716 0
3 COSM5611204 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 0
4 COSM5611206 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 0
5 COSM5611205 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 0
6 COSM5611187 WT1 skin,scalp,malignant melanoma,NS c.1253G>A p.W418* 11:32389155-32389155 0
7 COSM1703787 WT1 skin,neck,malignant melanoma,NS c.1169G>A p.R390Q 11:32392031-32392031 0
8 COSM5611184 WT1 skin,scalp,malignant melanoma,NS c.837C>T p.P279P 11:32400005-32400005 0
9 COSM5611196 WT1 skin,scalp,malignant melanoma,NS c.651G>A p.L217L 11:32427973-32427973 0
10 COSM5611193 WT1 skin,scalp,malignant melanoma,NS c.538G>A p.D180N 11:32428524-32428524 0
11 COSM3446776 WT1 skin,scalp,malignant melanoma,NS c.820G>A p.D274N 11:32400022-32400022 0
12 COSM5879179 WT1 skin,scalp,malignant melanoma,NS c.1288G>A p.E430K 11:32389120-32389120 0
13 COSM5611190 WT1 skin,scalp,malignant melanoma,NS c.528C>T p.F176F 11:32428534-32428534 0
14 COSM5611165 WRN skin,neck,malignant melanoma,NS c.1785C>A p.I595I 8:31090898-31090898 0
15 COSM5611174 WRN skin,scalp,malignant melanoma,NS c.3898C>T p.P1300S 8:31157446-31157446 0
16 COSM5611169 WRN skin,scalp,malignant melanoma,NS c.866C>T p.S289L 8:31080893-31080893 0
17 COSM3512552 VAT1L skin,neck,malignant melanoma,NS c.246C>T p.F82F 16:77816933-77816933 0
18 COSM5611155 VAT1L skin,scalp,malignant melanoma,NS c.430G>A p.E144K 16:77825312-77825312 0
19 COSM5611159 VAT1L skin,scalp,malignant melanoma,NS c.985G>A p.G329S 16:77884710-77884710 0
20 COSM5611154 VAT1L skin,scalp,malignant melanoma,NS c.503C>T p.A168V 16:77825385-77825385 0
21 COSM5611151 USP9X skin,scalp,malignant melanoma,NS c.3985T>C p.F1329L 23:41196279-41196279 0
22 COSM5611149 USP9X skin,scalp,malignant melanoma,NS c.5195C>T p.T1732I 23:41214594-41214594 0
23 COSM5611132 UGT1A1 skin,scalp,malignant melanoma,NS c.256G>A p.E86K 2:233760543-233760543 0
24 COSM5611117 TSHR skin,scalp,malignant melanoma,NS c.2043C>T p.F681F 14:81144101-81144101 0
25 COSM4819845 TSHR skin,scalp,malignant melanoma,NS c.291C>T p.F97F 14:81068302-81068302 0
26 COSM5611104 TSC2 skin,neck,malignant melanoma,NS c.626C>T p.T209I 16:2056222-2056222 0
27 COSM5611110 TSC2 skin,scalp,malignant melanoma,NS c.2109G>A p.W703* 16:2072252-2072252 0
28 COSM5611108 TSC2 skin,scalp,malignant melanoma,NS c.2632C>T p.P878S 16:2075885-2075885 0
29 COSM5611106 TSC2 skin,scalp,malignant melanoma,NS c.3347C>T p.A1116V 16:2079619-2079619 0
30 COSM5611095 TSC1 skin,scalp,malignant melanoma,NS c.995C>T p.S332F 9:132911487-132911487 0
31 COSM5611088 TSC1 skin,scalp,malignant melanoma,NS c.248C>T p.A83V 9:132925702-132925702 0
32 COSM5611093 TSC1 skin,scalp,malignant melanoma,NS c.1A>T p.M1L 9:132928872-132928872 0
33 COSM5611072 TRRAP skin,neck,malignant melanoma,NS c.9716C>T p.P3239L 7:98992171-98992171 0
34 COSM5611046 TRRAP skin,scalp,malignant melanoma,NS c.3407C>T p.P1136L 7:98930646-98930646 0
35 COSM5611024 TRRAP skin,scalp,malignant melanoma,NS c.5116C>G p.R1706G 7:98950119-98950119 0
36 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 0
37 COSM5611050 TRRAP skin,scalp,malignant melanoma,NS c.8151G>A p.E2717E 7:98976749-98976749 0
38 COSM5611070 TRRAP skin,neck,malignant melanoma,NS c.687C>T p.P229P 7:98899475-98899475 0
39 COSM5611064 TRRAP skin,neck,malignant melanoma,NS c.3048G>A p.K1016K 7:98927239-98927239 0
40 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 0
41 COSM5611048 TRRAP skin,scalp,malignant melanoma,NS c.8119C>T p.P2707S 7:98976717-98976717 0
42 COSM5611066 TRRAP skin,neck,malignant melanoma,NS c.4150G>C p.E1384Q 7:98937194-98937194 0
43 COSM5611080 TRRAP skin,scalp,malignant melanoma,NS c.3597C>T p.S1199S 7:98931410-98931410 0
44 COSM5611062 TRRAP skin,scalp,malignant melanoma,NS c.6763A>G p.M2255V 7:98964637-98964637 0
45 COSM5611056 TRRAP skin,scalp,malignant melanoma,NS c.1568C>T p.P523L 7:98910273-98910273 0
46 COSM5611044 TRRAP skin,scalp,malignant melanoma,NS c.3310G>A p.E1104K 7:98930123-98930123 0
47 COSM2779402 TRPM3 skin,scalp,malignant melanoma,NS c.2914G>A p.A972T 9:70553200-70553200 0
48 COSM5611009 TRPM3 skin,scalp,malignant melanoma,NS c.1797G>A p.L599L 9:70619008-70619008 0
49 COSM2779303 TRPM3 skin,neck,malignant melanoma,NS c.3620G>A p.R1207Q 9:70537073-70537073 0
50 COSM5610949 TRPM3 skin,scalp,malignant melanoma,NS c.4572G>A p.K1524K 9:70536121-70536121 0

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2
Show member pathways
13.75 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
3
Show member pathways
13.39 BRAF CASP3 CDKN1A FGF2 MMP2 NRAS
4
Show member pathways
13.02 CASP3 CDKN1A FGF2 MDM2 NRAS PTGS2
5
Show member pathways
12.99 CASP3 CDKN1A CDKN2A FGF2 MDM2 NRAS
6
Show member pathways
12.91 BRAF CASP3 CDKN1A CDKN2A MDM2 NRAS
7
Show member pathways
12.84 CASP3 CDKN1A CDKN2A MDM2 NRAS TP53
8 12.79 BRAF CASP3 FGF2 NRAS TP53
9
Show member pathways
12.79 BRAF CDKN1A CDKN2A CDKN2B FGF2 NRAS
10
Show member pathways
12.76 CDKN1A FGF2 MDM2 NRAS TP53
11
Show member pathways
12.75 BRAF CASP3 NRAS PTGS2 TP53
12
Show member pathways
12.63 BRAF CDKN1A MDM2 NRAS TP53
13
Show member pathways
12.62 CDKN1A FGF2 MMP2 NRAS TP53
14
Show member pathways
12.6 CDKN1A CDKN2A CDKN2B MDM2 TP53
15
Show member pathways
12.59 BRAF CASP3 MDM2 MMP2 NRAS TP53
16
Show member pathways
12.46 CASP3 MDM2 NRAS TP53
17 12.45 CASP3 CDKN1A CDKN2A MDM2 NRAS PTGS2
18
Show member pathways
12.45 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
19
Show member pathways
12.44 BRAF MITF NRAS PTGS2
20
Show member pathways
12.43 CASP3 CDKN1A CDKN2A MDM2 TP53
21 12.41 CDKN1A CDKN2A CDKN2B MDM2 TP53
22 12.4 CDKN1A CDKN2A CDKN2B NRAS TP53
23
Show member pathways
12.38 CDKN1A CDKN2A CDKN2B TP53
24
Show member pathways
12.3 BRAF CASP3 MITF NRAS TP53
25 12.28 CDKN1A MDM2 MITF TP53
26
Show member pathways
12.28 CASP3 CDKN1A MDM2 TP53
27
Show member pathways
12.24 BRAF CASP3 CDKN1A MDM2 NRAS TP53
28 12.19 BRAF CASP3 MDM2 TP53
29 12.19 CASP3 CDKN1A MDM2 NRAS TP53
30
Show member pathways
12.18 BRAF CASP3 NRAS TP53
31 12.17 BRAF CASP3 CDKN1A MMP2 PTGS2 TP53
32 12.17 CASP3 CDKN1A CDKN2A CDKN2B MDM2 NRAS
33 12.16 BRAF CASP3 CDKN1A FGF2 MDM2 MMP2
34
Show member pathways
12.14 BRAF CDKN1A CDKN2B MDM2 NRAS
35 12.14 CDKN1A CDKN2A CDKN2B MDM2 NRAS TP53
36 12.13 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
37 12.11 CDKN1A CDKN2A MDM2 MMP2 TP53
38 12.1 CDKN1A MDM2 MMP2 TP53
39 12.03 BRAF CASP3 NRAS PTGS2
40 12.03 CDKN1A CDKN2A MDM2 NRAS TP53
41 12.01 CDKN1A FGF2 MMP2 PTGS2 TP53
42 11.97 BRAF CDKN1A CDKN2A MDM2 TP53
43 11.92 CASP3 MMP2 NRAS
44 11.89 CASP3 CDKN1A CDKN2B PTGS2 TP53
45 11.89 BRAF CDKN1A CDKN2A MDM2 NRAS TP53
46 11.87 FGF2 MMP2 PTGS2
47 11.86 CDKN1A MDM2 TP53
48
Show member pathways
11.85 CDKN1A MDM2 TP53
49 11.83 CDKN1A MDM2 TP53
50
Show member pathways
11.83 BRAF CASP3 NRAS

GO Terms for Skin Melanoma

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 BRAF CDKN2A MDM2 MITF TP53
2 angiogenesis GO:0001525 9.89 FGF2 MCAM MMP2 PTGS2
3 response to drug GO:0042493 9.88 CASP3 CDKN1A MDM2 NME1 PTGS2
4 negative regulation of cell proliferation GO:0008285 9.85 CDKN1A CDKN2A CDKN2B NME1 PTGS2 TP53
5 cell cycle arrest GO:0007050 9.8 CDKN1A CDKN2A CDKN2B TP53
6 negative regulation of apoptotic process GO:0043066 9.8 BRAF CASP3 CDKN1A MDM2 MITF PTGS2
7 response to organic substance GO:0010033 9.79 CASP3 CDKN1A PTGS2
8 response to glucocorticoid GO:0051384 9.75 CASP3 CDKN1A PTGS2
9 cellular response to drug GO:0035690 9.74 BRAF NME1 TP53
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.72 CDKN1A MDM2 TP53
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 FGF2 MDM2 MMP2
12 response to cAMP GO:0051591 9.7 BRAF NME1 TYR
13 melanin biosynthetic process GO:0042438 9.61 PMEL TYR
14 response to antibiotic GO:0046677 9.61 CASP3 MDM2 TP53
15 negative regulation of fibroblast migration GO:0010764 9.6 BRAF FGF2
16 amyloid fibril formation GO:1990000 9.58 CDKN2A MDM2
17 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 CASP3 CDKN1A CDKN2A
18 signal transduction by p53 class mediator GO:0072331 9.51 CDKN1A TP53
19 negative regulation of phosphorylation GO:0042326 9.5 CDKN1A CDKN2A CDKN2B
20 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
21 cytokine-mediated signaling pathway GO:0019221 9.43 CASP3 CDKN1A FGF2 MMP2 PTGS2 TP53
22 replicative senescence GO:0090399 9.33 CDKN1A CDKN2A TP53
23 Ras protein signal transduction GO:0007265 9.02 CDKN1A CDKN2A FGF2 NRAS TP53

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....